Lung cancer drug brigatinib under Real-World watch in south korea
NCT ID NCT04592523
First seen Jan 04, 2026 · Last updated May 24, 2026 · Updated 23 times
Summary
This study monitors adults with advanced ALK-positive non-small cell lung cancer who are starting brigatinib for the first time. Researchers will track side effects and measure how often tumors shrink or disappear. The goal is to confirm the drug's safety and effectiveness in everyday use, not to find a cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Pusan National University Hospital
RECRUITINGBusan, 49241, South Korea
Conditions
Explore the condition pages connected to this study.